Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
I am looking for
added new label for I am looking for
Advanced Filters
Found 18 clinical trials
Flotetuzumab for Relapsed Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS) Following Allogeneic Hematopoietic Cell Transplantation (Allo-HCT)

in improved patient outcomes. Furthermore, administration of a donor lymphocyte infusion (DLI) (if available) in combination with MGD006 will be safe, tolerable and may provide additional therapeutic

  • 31 May, 2021
  • 1 location
Cytokine Induced Memory-like NK Cell Adoptive Therapy for Relapsed AML After Allogeneic Hematopoietic Cell Transplant

Donor Lymphocyte Infusion (DLI) following salvage chemotherapy is the one of the most widely used treatment approaches in patients who relapse after allogeneic hematopoietic cell transplant

  • 15 Apr, 2021
  • 1 location
T-cell Depleted Donor Lymphocyte Infusion (DLI)for Acute Myeloid Leukemia (AML) or High Risk Myelodysplastic Syndrome (MDS)

Primary Objectives: This a pilot project to determine the feasibility of the preemptive CD8+ depleted T-cell donor lymphocyte infusion (DLI) in: - Reducing the incidence of

donor lymphocyte infusion
myeloid leukemia
high risk myelodysplastic syndrome
bone marrow procedure
  • 07 Nov, 2020
  • 1 location
Daratumumab and Donor Lymphocyte Infusion in Treating Participants With Relapsed Acute Myeloid Leukemia After Stem Cell Transplant

myeloid leukemia that has come back after a stem cell transplant. A donor lymphocyte infusion is a type of therapy in which lymphocytes (white blood cells) from the blood of a donor are given to a

monoclonal protein
donor lymphocyte infusion
myeloid leukemia
white blood cells
  • 25 Jan, 2021
HMA+DLI vs DLI Preemptive Therapy Based on MRD for AL Undergoing Allo-HSCT

options for relapse include stopping immune suppression, re-induction of chemotherapy, donor lymphocyte infusion (DLI) or combination therapy. In this prospective randomized controlled study, the safety

  • 22 Jan, 2021
  • 1 location
Study to Evaluate the Safety of a Gene and Cell Therapy Product in Participants With HIV That is Well-Controlled on Antiretroviral Therapy

This is a Phase 1 study to assess the safety of a gene and cell therapy for autologous donor lymphocyte infusion in HIV+ participants with well-controlled viremia on antiretroviral therapy.

antiretroviral therapy
HIV Vaccine
  • 20 May, 2021
  • 2 locations
Extracorporeal Photopheresis Using Theraflex ECP for Patients With Refractory Chronic Graft Versus Host Disease (cGVHD)

Theraflex system in patients with refractory chronic graft versus host disease (cGVHD) after any type of hematopoietic stem cell transplantation or after donor lymphocyte infusion.

  • 21 Jan, 2021
  • 6 locations
Haploidentical Stem Cell Transplant With Prophylactic Natural Killer DLI for Lymphoma Multiple Myeloma and CLL

transplantation with Post-Transplant Cyclophosphamide. The study will also test the investigational use of CD56-enriched Donor Lymphocyte Infusion to see if this treatment is safe, and whether or not it will help

chemotherapy regimen
aggressive non-hodgkin's lymphoma
multiple myeloma
t-cell lymphoma
  • 23 Jun, 2021
  • 1 location
Chemotherapy and DLI for Prevention of Second Relapse in Patients With Relapsed Acute Leukemia After Allotransplant

receiving DLI (donor lymphocyte infusion)for leukemia relapse after a first allotransplant have a lower likelihood of a second relapse compared with similar patients not developing chronic GvHD. And, our

minimal residual disease
chronic graft versus host disease
donor lymphocyte infusion
acute leukemia
residual disease
  • 23 Jan, 2021
  • 1 location
Blinatumomab Plus HLA-Mismatched Cellular Therapy for Relapsed/Refractory CD19+ ALL

blood mononuclear cells collected via pheresis from a haploidentical family member - the procedure is analogous to giving a donor lymphocyte infusion outside of the setting of an allogeneic stem cell

cellular therapy
stem cell transplantation
gilbert's syndrome
flow cytometry
  • 14 Feb, 2021
  • 1 location